One limitation of this study is that the total number of subjects was small, as we excluded patients with systemic diseases that might affect CRP levels such as cardiovascular disease, diabetes, arthritis, and uncontrolled systemic disease. This evidence concerns the gene CRP and arthritic joint disease.